Guest Editors
Chenyu Sun
AMITA Health Saint Joseph Hospital Chicago
Dr. Chenyu Sun completed medical education from Anhui Medical University, China and then obtained Master of Science degree in Translational Medical Research from Heidelberg University, Germany. He completed postgraduate medical training in Chicago, and was conferred the degree of Doctor of Medicine. Dr. Sun is now a registered doctor in Illinois and New York State. He has been actively involved in research as a physician scientist and has numerous publications. He has broad research interests including the surgical and medical oncology, gastroenterology, as well as public health field and research related to COVID-19.
Ruiqin Han
State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Dr. Ruiqin Han graduated from Peking Union Medical College and completed post- doctoral training in the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. He is currently the director of the pathology platform of the State Key Laboratory of Medical Molecular Biology of the Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Han research focus includes the diagnosis, treatment, and prognosis of malignant tumors, especially the excavation and verification of tumor diagnosis and prognostic markers, as well as the tumor microenvironment. Dr. Han is the youth member of the Cancer Markers Committee of the China Anti-Cancer Association and the Neurodegenerative Diseases Professional Committee of the China Microcirculation Society.
Liang Gao
Center for Clinical Medicine, Huatuo Institute of Medical Innovation (HTIMI), Berlin, Germany
Dr. Liang Gao is currently the Executive Director & Chair of Center of Clinical Medicine, Huatuo Institute of Medical Innovation (HTIMI), Germany. Previously, he studied human medicine in China and Germany with fellowship training in both Asia and Europe. He was trained to be clinician-scientist at Anhui Medical University (China), Peking University (China), Heidelberg University (Germany), and Saarland University (Germany). His research focuses on the clinical development of advanced therapy medicinal products (ATMPs) for musculoskeletal conditions and oncological diseases.
Vicky Yau
Columbia University Irving Medical Center, Division of Oral and Maxillofacial Surgery, New York, NY 10032, USA
Dr. Vicky Yau graudated from Stony Brook University School of Dental Medicine with a Doctor of Dental Surgery. She currently works at at NewYork-Presbyterian/Columbia Irving Medical Center and she has broad interest in the areas of head and neck cancer, oral squamous cell carcinoma, craniofacial reconstruction and orofacial pain. She has multiple publications on tumor microenvironment analysis, diagnostic markers and neurological diseases.
Collection Overview
Cancer has become a serious burden on the health system, society, and patients worldwide due to the constant increase in newly diagnosed cancer cases. One drawback in cancer research is the lack of an ideal model system to investigate cancer transformation and treatment. Despite significant advances in the development of anti-tumor drugs, many potential drugs did not successfully pass all three phases of clinical trials. One of the problems is a lack of suitable in vivo models. Researchers often use human tumor cell lines or tumor animal models of patient-derived tumors transplanted into immune-deficient mice. Cancer cell line-based xenotransplantation (CDX) describes animal models established with human tumor cell lines. In contrast, patient-derived tumor xenotransplantation (PDX) describes animal models established with patient-derived tumors. A PDX model is constructed by transplanting the tumor tissues of cancer patients directly to immune-deficient mice. These models retain the characteristics of most primary tumors at the histopathological, molecular biological, and genetic levels, which results in better predictability of clinical efficacy. Therefore, the PDX model is widely used to develop new drugs, especially in pre-clinical studies to explore targeted drugs and develop patient screening methods and biomarkers. As a result, this special issue aims to provide a platform for researchers to contribute classic, optimized, and newly developed PDX model-building methods. We welcome all related protocols and manuscripts in the related field.
